
Queensland will not reconsider its ban on puberty blockers for young people with gender dysphoria, despite federal health minister Mark Butler urging the state to do so. This stance comes amidst growing national discussions on the accessibility of gender-affirming care for youth.
The state’s health minister, Tim Nicholls, said Queensland’s position on the drugs remains unchanged, even after the National Health and Medical Research Council (NHMRC) provisionally recommended prescribing puberty suppressants to young trans and gender diverse Australians. The NHMRC’s guidance is seen as a significant step toward standardizing care across the country, but Queensland remains an outlier in its approach.
Federal recommendation met with state resistance
On Monday, Butler announced the NHMRC‘s interim advice, which conditionally recommended considering gonadotropin-releasing hormone agonists for patients with gender incongruence under 18. It came with several caveats, including that the young person has been diagnosed with gender incongruence, has commenced puberty (defined as Tanner stage 2 or later), and is assessed as suitable for treatment in collaboration with clinicians. These criteria aim to ensure that treatment is both medically appropriate and individually tailored.
The advice also emphasized the importance of shared decision-making between the patient, their parent or guardian, and the treating clinician. However, a spokesperson for Nicholls reiterated that the state’s position remains unchanged, and they will continue to prioritize the health, safety, and wellbeing of young Queenslanders. This prioritization, however, has been criticized for potentially delaying access to necessary care for some youth.
Ban remains in place pending UK trial results
Queensland banned the prescription of puberty blockers in public hospital gender clinics in 2025, pending the results of the UK PATHWAYS TRIAL, which are not expected until 2031. This decision was made despite a government-commissioned independent review that warned the ban would not strengthen research or monitor quality of care and carried legal, ethical, and social risks related to equitable access.
The decision has been criticized by medical professionals, including AMA Queensland president Erica Gannon, who said the ban has caused significant harm to children, their families, and clinicians. Gannon urged the government to act in accordance with science and follow the NHMRC’s advice, emphasizing that these treatments are often time-sensitive and key for mental and emotional wellbeing.
Medical community welcomes federal guidance
The Australian Professional Association for Trans Health (AusPATH) and LGBITQ+ Health Australia welcomed the NHMRC’s provisional guidance. AusPATH CEO Eloise Brook said the use of puberty suppressants is one possible part of care and that it is not necessary to wait until a young person is distressed before providing care. She also highlighted the importance of early intervention in preventing long-term psychological harm.
Brook noted that the Australian Standards of Care and Treatment Guidelines for Trans and Gender Diverse Children and Adolescents, developed by the Royal Children’s Hospital Melbourne, provide a key framework for clinical practice. She emphasized that the NHMRC’s advice complements these standards, supporting evidence-informed decision-making and high-quality care. Consistency in healthcare delivery, she argued, is vital to ensure young people and families can access appropriate support regardless of their location. The NHMRC advice will be open to consultation until early 2027, allowing for further refinement and input from stakeholders.